Search Results
May 03, 2026, 08:43 ET Spinogenix to Present Preclinical Results at ARVO 2026 Demonstrating Neuroprotective Effects of Tazbentetol in Glaucoma and Diabetic Retinopathy Models
retinal degeneration and synapse loss in ways that mirror the effects of glaucoma and DR in humans.Mice in each study received daily tazbentetol (30mg/kg i.p.) or control treatment for eight weeks, during which elevations in IOP (MB mouse) and blood sugar (db/db mouse) were monitored to confirm
More news about: Spinogenix
May 01, 2026, 16:05 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL. Please see full
More news about: Neurocrine Biosciences, Inc.
May 01, 2026, 15:03 ET Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®
two prefilled pen formats:A pen delivering 0.25 mg or 0.5 mg doses (containing 2 mg of semaglutide 0.68mg/mL)A pen delivering 1 mg doses (containing 4 mg of semaglutide 1.34 mg/mL)In Canada, Apo‑Semaglutide Injection (semaglutide injection) is
More news about: Apotex Inc.
May 01, 2026, 09:05 ET New Chapter Expands Retail Presence at Erewhon with Three Targeted Wellness Supplements: Zyflamend, Daily Skin Renewal, and Omega-7 Sea Buckthorn Blend
Gluten-Free • Where Food Comes From Certified OrganicOmega-7 Sea Buckthorn BlendAn expertly formulated beauty blend, delivering 100 mg of plant-sourced Omega-7 fatty acids – one of nature's good fats sourced exclusively from organic sea buckthorn fruit – combined with complementary supercritical
More news about: New Chapter
May 01, 2026, 08:37 ET Cellular Glutathione Shines During Stress Awareness Month
Continual-G contains a proprietary formulation of GGC, Glyteine ®, which will boost your cellular glutathione in a dose-dependent manner, where a single 400 mg dose in capsule or beverage powder form will give up to a 25% increase within 2 hours. These increases provide your cells with more antioxidant power
More news about: Continual-G
May 01, 2026, 08:04 ET Novo Nordisk's Ozempic® pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US
(semaglutide) tablets 3 mg, 7 mg, and 14 mg. The original strengths have been reformulated and are now being introduced as Ozempic® (semaglutide) tablets 1.5 mg, 4 mg, and 9 mg. The new Ozempic® pill works similarly to semaglutide tablets 3 mg, 7 mg, and 14 mg and has the same efficacy
More news about: Novo Nordisk
May 01, 2026, 07:30 ET Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at Digestive Disease Week
hepatorenal syndrome with rapid reduction in kidney function.LIMITATION OF USEPatients with a serum creatinine >5 mg/dL are unlikely to experience benefit.IMPORTANT SAFETY INFORMATIONWARNING: SERIOUS OR FATAL RESPIRATORY FAILURE
More news about: Keenova Therapeutics
May 01, 2026, 00:23 ET Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
of both IRF and SRF by Week 8. Responses were consistent irrespective of different underlying etiologies. Based on these positive results, the 5 mg and 10 mg dose levels have advanced into the actively recruiting Phase 3 PEAK and PINNACLE studies.Ocular Inflammatory DiseaseOcular
More news about: Kodiak Sciences Inc.
Apr 30, 2026, 23:22 ET 歷史性首次：Gordonstoun Japan成立暨「變革領導力暑期項目」啟動
https://www.gordonstoun.jp/en/program/圖片：https://cdn.kyodonewsprwire.jp/prwfile/release/M109071/202604207731/_prw_PI1fl_mg0nW980.png以培育英國王室多代成員（包括國王查爾斯三世、已故菲利普親
More news about: OCC Educational Corporation Limited
Apr 30, 2026, 22:40 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
18.57%, to close at $5.50 per share on March 5, 2026. Then, on March 30, 2026, PepGen issued a press release announcing "clinical data from the 5 mg/kg multiple ascending dose cohort (MAD) of the ongoing Phase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1 (DM1)." Although PepGen
More news about: Pomerantz LLP
Apr 30, 2026, 15:49 ET Wegovy® é mais eficiente em preservar massa muscular durante a perda de peso, mostram novos estudos de vida real
Neste momento, estão em aprovação da Anvisa, no Brasil, o pedido de nova forma oral de semaglutida na dosagem de 25 mg com uso diário e a injeção semanal de Wegovy® na nova dosagem de 7,2 mg.Referências: Oliveira L. Wegovy pode preservar melhor a massa corporal
More news about: Novo Nordisk
Apr 30, 2026, 09:00 ET Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual Meeting
trials. These trials evaluated the safety and efficacy of monthly 2 mg intravitreal administration of IZERVAY in patients with GA secondary to AMD. For the first 12 months in both trials, patients were randomized to receive either IZERVAY 2 mg or sham monthly. There were 286 participants enrolled in GATHER1
More news about: Astellas Pharma Inc.
Apr 30, 2026, 08:00 ET Stealth BioTherapeutics Provides Commercial Launch Update and Pipeline Progress Across Mitochondrial Disease Portfolio
gasping syndrome) have occurred in preterm and low–birth weight neonates receiving benzyl alcohol (BA)-containing drugs.FORZINITY contains 20 mg BA/mL and is not approved for use in neonates or for IV administration.HypersensitivityReported reactions include rash, papular
More news about: Stealth BioTherapeutics Inc.
Apr 29, 2026, 23:13 ET D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
Elisrasib monotherapy demonstrates notable efficacy in three major tumor types at its recommended phase 2 dose (RP2D, 600 mg QD). Phase 2 clinical outcomes include:2L+ KRAS G12Ci–naïve NSCLC: ORR of 58.8%, mPFS of 12.2 months2L+
More news about: D3 Bio
Apr 29, 2026, 16:05 ET Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
included a four-week screening period, a 24-week treatment period during which participants received 40 mg of INGREZZA once-daily for the first four weeks, followed by flexible dosing of 40 mg, 60 mg or 80 mg once-daily based on individual treatment needs and a two-week safety follow-up period. Baseline socio-demographic
More news about: Neurocrine Biosciences, Inc.
Apr 29, 2026, 16:05 ET Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
participants were rapidly titrated to 90 mg daily doses. After four weeks of daily dosing at 90 mg, participants were down-titrated to 30 mg daily doses and maintained at 30 mg daily for seven weeks. Weight loss in this cohort was shown to be rapid and progressive through the 90 mg treatment period and was further
More news about: Viking Therapeutics, Inc.
Apr 29, 2026, 10:00 ET European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
(2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1
More news about: Henlius
Apr 29, 2026, 08:47 ET JackRabbit Launches MG Cargo: The 55 lb Cargo Electric Bike That Carries 10x Its Weight
Copilot Kit for MG Cargo includes a passenger seat and handlebar, transforming the MG Cargo into a school pickup hero or neighborhood memory-maker. Supports passengers up to 150 lbs.Side Rack Kit for MG CargoThe new
More news about: JackRabbit Mobility, Inc.
Apr 29, 2026, 06:09 ET 復宏漢霖與Organon共同宣佈歐洲首個帕妥珠單抗生物類似藥POHERDY®獲歐盟委員會批准
2026年4月29日 /美通社/ -- 復宏漢霖（2696.HK）與 Organon（紐交所代碼：OGN）今日聯合宣佈，歐盟委員會（European Commission, EC）已批准POHERDY®（帕妥珠單抗）420 mg/14 mL靜脈注射液的上市許可。該產品是歐洲首個且目前唯一獲批的PERJETA（帕妥珠單抗）生物類似藥，獲批適用於參比制劑的全部適應症[1]。 Organon副總裁、全球生物類似藥商業負責人Joe Azzinaro表示：「作為歐洲首個且目前唯一獲批的帕妥珠單抗
More news about: 復宏漢霖
Apr 28, 2026, 16:05 ET PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
PIVOT-HD extension study in which those originally randomized to receive 5 mg or 10 mg of votoplam remained on those dose levels. Participants initially randomized to receive placebo were randomized to receive 5 mg or 10 mg. All participants and investigators remain blinded to initial PIVOT-HD treatment
More news about: PTC Therapeutics, Inc.
Apr 28, 2026, 12:46 ET Anvisa aprova Rybelsus®, semaglutida oral da Novo Nordisk, para redução do risco cardiovascular em adultos
jornada completa do tratamento, adaptando prescrição médica às necessidades de cada paciente. Na compra de duas caixas de qualquer dosagem (3 mg, 7 mg ou 14 mg), o custo mensal do tratamento sai por R$ 575,00 (e-commerce) ou R$ 625,00 (em lojas físicas). Dessa forma, o paciente pode economizar por volta
More news about: Novo Nordisk
Apr 28, 2026, 10:00 ET Introducing GateDrop: New Energy Gummies Are Changing How You Get Your Lift
dosedMade with all-natural caffeine from green, unroasted coffee beans, GateDrop energy gummies deliver clean, precisely dosed energy – 25 mg of caffeine per gummy, plus added vitamins – in convenient packaging and great-tasting flavors like Mixed Berry. Vegan and gluten-free, with just 35
More news about: GateDrop
Apr 28, 2026, 09:28 ET PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
extension study in which all subjects would receive votoplam. Those originally randomized to 5mg and 10mg would continue at that dose level; those initially randomized to placebo would be randomized 1:1 to 5mg or 10mg. All subjects and investigators remain blinded to initial treatment assignment.About
More news about: PTC Therapeutics, Inc.
Apr 28, 2026, 09:00 ET FRISS Launches a New Way to Activate Focus with Clean Energy Caffeine Pouches
brand, the brand brings a new level of trust, rigor, and legitimacy to the performance space.FRISS is available in two caffeine strengths, 75mg and 100mg, and comes in a variety of flavors, including:Fresh MintEspresso MacchiatoColaStrong MintEnergyThe
More news about: FRISS
Apr 28, 2026, 09:00 ET Cadence OTC Launches First-of-Its-Kind UTI Emergency Relief Kit at Walmart Stores
relief12 methenamine tablets for infection controlFour pH Power Flush packets containing 1,500mg ascorbic acid (Vitamin C), whole cranberries equivalent to 36mg proanthocyanidins (PACs), and 2,000mg D-mannose* The statements about the dietary supplement bundled in the Cadence UTI
More news about: Cadence OTC